Advanced Enzyme Technologies Limited has informed the Exchange about Transcript
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported its highest-ever quarterly and annual revenue for FY26 ended March 2026. Q4 revenue stood at INR 2,034 million (22% YoY growth) and full-year revenue at INR 7,458 million (17% growth). EBITDA remained strong at 31% margins for both quarter and full year, with PAT growing 30% YoY to INR 1,736 million. All segments delivered healthy growth: Human Healthcare (63% of revenue), Animal Healthcare (13%), Bioprocessing (16% growth), and Specialized Manufacturing (23% growth). Management acknowledged near-term margin pressures from rising input costs (fuel, salt, solvents, packaging, logistics) due to geopolitical disruptions but expects to maintain steady margins through cost efficiency and productivity improvements. The company targets double-digit growth for FY27, anticipating growth from Indian markets and all business segments despite a challenging U.S. environment.
The company demonstrated robust growth and margin improvement in FY26 with broad-based segment performance. However, management's explicit acknowledgment of margin pressures from input cost inflation and the challenging U.S. market outlook suggests caution. Investors should monitor whether the company can successfully pass on costs or maintain margins in FY27.